C-Peptide

What is C-Peptide?

C-peptide is a byproduct made in equal amounts to insulin when your pancreas processes proinsulin.

Your pancreas doesn't make insulin directly. Beta cells first produce a longer molecule called proinsulin, and an enzyme splits it into two pieces: insulin and C-peptide, in a 1:1 ratio (StatPearls / NCBI Bookshelf, 2023). Because both pieces are released together, a C-peptide measurement works as a proxy for how much insulin your body is manufacturing on its own, whether or not you're currently injecting insulin. The two molecules don't stick around the same length of time. Insulin gets cleared from blood within 5 to 10 minutes because the liver grabs and breaks it down fast. C-peptide has almost no first-pass liver clearance and is instead cleared by the kidneys, giving it a half-life closer to 30 to 35 minutes (StatPearls / NCBI Bookshelf, 2023). That gap is the whole reason the test exists: it's a steadier signal than insulin itself, and it keeps working even in someone using insulin therapy, where a direct insulin measurement would just reflect the injected dose. Labs run it three ways: fasting, random, or "stimulated," where you get a glucagon injection or a mixed meal and then get sampled again 90 to 120 minutes later. A stimulated test pushes the pancreas and shows what reserve capacity is left, which a single fasting draw can miss (MedlinePlus, 2025; StatPearls, 2023). A newer, non-invasive variant is the urinary C-peptide creatinine ratio, or UCPCR: a spot urine sample taken about two hours after a meal, adjusted for creatinine to control for how concentrated the urine is. It's used mainly in research and specialist settings to help sort out diabetes type without a blood draw.

Typical reference context

Different labs use different assays, units, and cutoffs, so the number printed on your report is the one that matters, next to the reference range that same lab prints beside it. This table is general orientation, not a substitute for that.

What changed recently

The American Diabetes Association's Standards of Care in Diabetes—2026 dropped a prior gatekeeping rule: it states there should be no requirement for a specific C-peptide level, autoantibody status, or minimum duration of insulin treatment before someone starts an insulin pump or automated insulin delivery system (ADA Standards of Care in Diabetes—2026, Diabetes Care, Dec 2025/Jan 2026). That's a real access change, not a change in what the test measures.

Separately, a November 2023 individual-participant meta-analysis in The Lancet Diabetes & Endocrinology, pooling data from disease-modifying therapy trials in newly diagnosed type 1 diabetes, found that participants who retained more stimulated C-peptide also tended to run lower HbA1c, supporting the case for using C-peptide as a trial endpoint rather than just a diagnostic curiosity (Lancet Diabetes & Endocrinology / C-Path Type 1 Diabetes Consortium, Nov 7, 2023).

Tests often checked alongside this

• Fasting glucose or HbA1c — shows the downstream effect of whatever insulin production the C-peptide result reflects.
• Islet autoantibodies (GAD, IA-2, ZnT8) — distinguishes autoimmune beta-cell loss from other causes of a low result.
• Insulin — drawn at the same time, so comparing the two flags whether injected or oral insulin secretagogues are in the picture.
• Proinsulin — helps interpret results in research settings where the insulin-to-C-peptide split itself is in question.
• Serum or plasma glucose, drawn simultaneously with C-peptide — a low glucose alongside an elevated C-peptide is the pattern used in hypoglycemia workups for insulinoma.

What can affect this marker

• Kidney function: since the kidneys clear C-peptide, reduced renal clearance can raise measured levels independent of pancreatic output (StatPearls, 2023).
• Recent food intake: a random or post-meal draw runs higher than a fasting one because a meal stimulates insulin, and therefore C-peptide, release.
• Sulfonylurea medications: these stimulate the pancreas directly, which raises C-peptide the same way a meal does.
• Obesity and insulin resistance: both are linked to higher circulating insulin and C-peptide in population studies.
• Assay method: different C-peptide immunoassays aren't fully interchangeable, which is part of why reference ranges vary between labs.

What to track over time

• The exact value and unit your lab used (ng/mL versus nmol/L aren't interchangeable without conversion).
• Whether the draw was fasting, random, or stimulated, since that changes what a "normal" number looks like.
• The reference range printed on that specific report.
• Any medication changes (insulin, sulfonylureas) between draws, since those shift the result independent of pancreatic function.

What to ask your doctor

• Was this C-peptide test fasting, random, or stimulated, and does that change how you're reading it?
• How does this result fit with my glucose or HbA1c from around the same time?
• Is a repeat test, or a different type of C-peptide test, useful given my history?
• Does my kidney function affect how this result should be read?
• Is there a reason to also check autoantibodies alongside this?

This glossary entry is for informational purposes only and is not a substitute for professional medical advice. Read our Terms of Use.

Frequently asked questions